Stocks Health care RVMD
NASDAQ · Health careRevolution Medicines, Inc. (RVMD)
It posted a net loss of $1.8B. In fiscal 2025 capital spending exceeded operating cash flow by $913.7M. At June 30, 2026 it held $815.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
Key facts about Revolution Medicines, Inc.
- Net worth
- Revolution Medicines, Inc. has a market value (market cap) of $44.5B at the latest share price, and shareholders' equity of $2.6B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0, with a net loss of $1.1B.
- Cash flow
- In fiscal 2025 operations used $897.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 5, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Revolution Medicines, Inc.'s next report is expected around November 4, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Revolution Medicines, Inc. does
Revolution Medicines is a clinical-stage oncology company that develops targeted therapies for cancer patients. The company focuses on developing small-molecule inhibitors that target the RAS pathway, a biochemical signalling pathway frequently mutated in difficult-to-treat cancers such as pancreatic, non-small cell lung, and colorectal cancers. Its shares trade on NASDAQ under the ticker RVMD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$1.1B | -$5.95 | -$913.7M |
| 2024 | $0 | -$600.1M | -$3.58 | -$567.7M |
| 2023 | $11.6M | -$436.4M | -$3.86 | -$358.3M |
| 2022 | $35.4M | -$248.7M | -$3.08 | -$235.2M |
| 2021 | $29.4M | -$187.1M | -$2.57 | -$153.7M |
| 2020 | $43M | -$108.2M | -$2.01 | -$103M |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Revolution Medicines, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 1, 2026
- August 26, 2026Other event 8-K
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake (5% or more) SCHEDULE 13G
- August 5, 2026
- August 5, 2026
- July 29, 2026Passive stake (5% or more) SCHEDULE 13G
- June 22, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Revolution Medicines, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $78M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 29, 2026 | Sandler Alan B.Chief Development Officer | Exercised options | 6,000 | $353K |
| September 29, 2026 | Sandler Alan B.Chief Development Officer | Soldpre-planned (10b5-1) | 2,200 | $441.8K |
| September 29, 2026 | Sandler Alan B.Chief Development Officer | Soldpre-planned (10b5-1) | 1,609 | $324.6K |
| September 29, 2026 | Sandler Alan B.Chief Development Officer | Soldpre-planned (10b5-1) | 1,000 | $202.8K |
| September 29, 2026 | Sandler Alan B.Chief Development Officer | Soldpre-planned (10b5-1) | 1,199 | $244.5K |
| September 29, 2026 | Sandler Alan B.Chief Development Officer | Soldpre-planned (10b5-1) | 301 | $61.6K |
| September 25, 2026 | Cislini JeffSVP & General Counsel | Soldpre-planned (10b5-1) | 765 | $158.6K |
| September 25, 2026 | Mancini AnthonySee Remarks | Exercised options | 3,121 | $104.9K |
Who owns RVMD
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Dapice Joshua J.13G, passive with 30 related filers | 7.5% | February 9, 2026 |
| Farallon Capital Management, L.L.C.13G, passive with 28 related filers | 6.4% | August 13, 2026 |
| Baker Bros. Advisors LP13G, passive with 3 related filers | 5.3% | August 14, 2026 |
| JANUS HENDERSON GROUP Ltd.13G, passive | 5.1% | August 13, 2026 |
| Fmr LLC13G, passive with 1 related filers | 5% | November 5, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 690 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 13,695,790 | +2,483,084 |
| Farallon Capital Management, L.L.C. | 13,550,796 | -54,000 |
| Fmr LLC | 12,200,422 | +3,736,108 |
| Baker Bros. Advisors LP | 11,443,357 | +1,888,000 |
| Darwin Global Management, Ltd. | 10,629,822 | +8,418,804 |
| Jupiter Topco LLC | 10,736,145 | new |
| Vanguard Capital Management LLC | 9,088,661 | +726,377 |
| Vanguard Portfolio Management LLC | 8,294,855 | +792,232 |
| Nextech Invest Ltd. | 7,601,087 | 0 |
| Paradigm Biocapital Advisors LP | 6,361,323 | -294,380 |
| UBS Group AG | 5,448,364 | +1,061,573 |
| State Street Corp | 4,897,051 | +494,389 |
| Capital World Investors | 4,008,244 | new |
| Geode Capital Management, LLC | 3,942,676 | +604,534 |
| Wellington Management Group Llp | 3,843,415 | -2,184,404 |
| Jpmorgan Chase & Co | 3,298,066 | +2,996,673 |
| Bvf Inc | 2,965,160 | +108,378 |
| Alphabet Inc. | 2,946,619 | -345,906 |
| Casdin Capital, LLC | 2,577,333 | 0 |
| Deerfield Management Company, L.P. | 2,392,000 | +95,000 |
Insiders
16 insiders reported holding 3,821,752 shares in total, about $793.7M at the last price.
| Holder | Shares |
|---|---|
| Borisy AlexisDirector | 2,340,075 |
| Goldsmith Mark ASee Remarks, Director | 314,76661,424 held indirectly |
| Kelsey Stephen MichaelSee Remarks | 286,307 |
| Horn Margaret AChief Operating Officer | 149,680 |
| Anders JackChief Financial Officer | 119,216 |
| Wang XiaolinSee Remarks | 116,063 |
| Wei LinChief Medical Officer | 101,366 |
| Horning SandraDirector | 97,765 |
| Kim Lorence H.Director | 74,281 |
| Sandler Alan B.Chief Development Officer | 52,559 |
Questions about RVMD
What does Revolution Medicines, Inc. do?
Revolution Medicines is a clinical-stage oncology company that develops targeted therapies for cancer patients. The company focuses on developing small-molecule inhibitors that target the RAS pathway, a biochemical signalling pathway frequently mutated in difficult-to-treat cancers such as pancreatic, non-small cell lung, and colorectal cancers. Its shares trade on NASDAQ under the ticker RVMD.
What is Revolution Medicines, Inc.'s net worth?
Revolution Medicines, Inc. has a market value (market cap) of $44.5B at the latest share price, and shareholders' equity of $2.6B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Revolution Medicines, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $1.8B.
When did Revolution Medicines, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 1, 2026.
When is Revolution Medicines, Inc.'s next earnings report?
Revolution Medicines, Inc.'s next report is expected around November 4, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare RVMD with
Follow RVMD
Get an email when Revolution Medicines, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow RVMD: get an email when it filesWhere the numbers come from
Financial figures are the values Revolution Medicines, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.